Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate

References

• Bainbridge JL, Miravalle A, Corboy JR. Multiple sclerosis. In: DiPiro J, Talbert RL, Yee G, et al., editors. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill Medical; 2014. p 835-54
   Google Scholar
• Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014;89:225-40
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. What is MS? 2016. Available at: http://www.nationalmssociety.org/What-is-MS. [Last accessed 8 March 2016]
   Google Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ 2012;15:601-9
   PubMedGoogle Scholar
• Cohen BA, Coyle PK, Leist T, et al. Therapy optimization in multiple sclerosis: a cohort study of therapy adherence and risk of relapse. Mult Scler Relat Disord 2015;4:75-82
   Web of Science ®Google Scholar
• Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342-50
   PubMed Web of Science ®Google Scholar
• Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-20
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
   PubMed Web of Science ®Google Scholar
• Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83
   PubMed Web of Science ®Google Scholar
• Remington G, Rodriguez Y, Logan D, et al. Facilitating medication adherence in patients with multiple sclerosis. Int J MS Care 2013;15:36-45
   PubMedGoogle Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Agashivala N, Wu N, Abouzaid S, et al. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol 2013;13:138
   PubMed Web of Science ®Google Scholar
• Bergvall N, Petrilla AA, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ 2014;17:696-707
   PubMedGoogle Scholar
• Ontaneda D, Hara-Cleaver C, Rudick RA, et al. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci 2012;323:167-72
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Brara SM, Beaber BE, et al. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology 2013;80:1734-9
   PubMed Web of Science ®Google Scholar
• Kurtzke JF, Beebe GW, Norman JE Jr. Epidemiology of multiple sclerosis in US veterans: 1. Race, sex, and geographic distribution. Neurology 1979;29:1228-35
   PubMed Web of Science ®Google Scholar
• Wallin MT, Culpepper WJ, Coffman P, et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 2012;135:1778-85
   PubMed Web of Science ®Google Scholar
• Kister I, Chamot E, Bacon JH, et al. Rapid disease course in African Americans with multiple sclerosis. Neurology 2010;75:217-23
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Ramanathan M, Hashmi K, et al. Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology 2010;74:538-44
   PubMed Web of Science ®Google Scholar
• Amezcua L, Lund BT, Weiner LP, et al. Multiple sclerosis in Hispanics: a study of clinical disease expression. Mult Scler 2011;17:1010-16
   PubMed Web of Science ®Google Scholar
• Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, et al. Comparisons of Latinos, African Americans, and Caucasians with multiple sclerosis. Ethn Dis 2010;20:451-7
   PubMed Web of Science ®Google Scholar
• Cree BA, Reich DE, Khan O, et al. Modification of multiple sclerosis phenotypes by African ancestry at HLA. Arch Neurol 2009;66:226-33
   PubMedGoogle Scholar
• Cree BA, Al-Sabbagh A, Bennett R, et al. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol 2005;62:1681-3
   PubMed Web of Science ®Google Scholar
• Klineova S, Nicholas J, Walker A. Response to disease modifying therapies in African Americans with multiple sclerosis. Ethn Dis 2012;22:221-5
   PubMed Web of Science ®Google Scholar
• Rolnick SJ, Pawloski PA, Hedblom BD, et al. Patient characteristics associated with medication adherence. Clin Med Res 2013;11:54-65
   PubMedGoogle Scholar
• Khan O, Williams MJ, Amezcua L, et al. Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract 2015;5:132-42
   PubMedGoogle Scholar
• Avasarala J. Inadequacy of clinical trial designs and data to control for the confounding impact of race/ethnicity in response to treatment in multiple sclerosis. JAMA Neurol 2014;71:943-4
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Long-term care hospital PPS 2013. Baltimore, MD: US Centers for Medicare & Medicaid Services. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/LongTermCareHospitalPPS/index.html. [Last accessed 25 May 2016]
   Google Scholar
• Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002;8:469-76
   PubMedGoogle Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010;13:618-25
   PubMedGoogle Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74; discussion 75–7
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Durant RW, Legedza AT, Marcantonio ER, et al. Different types of distrust in clinical research among whites and African Americans. J Natl Med Assoc 2011;103:123-30
   PubMed Web of Science ®Google Scholar
• Diaz V. Encouraging participation of minorities in research studies. Ann Fam Med 2012;10:372-3
   PubMed Web of Science ®Google Scholar
• Munoz-Culla M, Irizar H, Otaegui D. The genetics of multiple sclerosis: review of current and emerging candidates. Appl Clin Genet 2013;6:63-73
   PubMedGoogle Scholar
• Minden SL, Hoaglin DC, Hadden L, et al. Access to and utilization of neurologists by people with multiple sclerosis. Neurology 2008;70:1141-9
   PubMed Web of Science ®Google Scholar
• Shabas D, Heffner M. Multiple sclerosis management for low-income minorities. Mult Scler 2005;11:635-40
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cutter G, Tyry T, et al. Does multiple sclerosis-associated disability differ between races? Neurology 2006;66:1235-40
   PubMed Web of Science ®Google Scholar